'Personalized medicine' to identify genetic risks for type 2 diabetes and focus prevention: Can it fulfill its promise?

Health Affairs

Volumn 31, Issue 1, 2012, Pages 43-49

  Spiegel, Allen M ^a   Hawkins, Meredith ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DNA;

ACCURACY; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; COLONOSCOPY; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DIABETES MELLITUS; DIABETIC RETINOPATHY; DNA REPAIR; GENE MUTATION; GENE SEQUENCE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; LASER SURGERY; LIFESTYLE; MAMMOGRAPHY; METABOLOMICS; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PREGNANCY DIABETES MELLITUS; PREVENTION; PROTEOMICS; PUBLIC HEALTH;

COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TAIWAN;

EID: 84855687590     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2011.1054     Document Type: Article

References (35)

1. Centers for Disease Control and Prevention. Diabetes: successes and opportunities for population-based prevention and control at a glance, 2001 [Internet]. Atlanta (GA): CDC; [last updated 2011 Aug 1; cited 2011 Nov 29]. Available from: http://www.cdc.gov/chronicdisease/resources/publications/AAG/ddt.htm
2. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta (GA): CDC; 2011.
3. Tulloch JA. Diabetes mellitus in the tropics. Edinburgh: E. and J. Livingstone; 1962.
4. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378(9785):31-40.
5. DeFronzo RA, Abdul-Ghani MA. Preservation of β-cell function: the key to diabetes prevention. J Clin Endocrinol Metab. 2011;96(8): 2354-66.
6. Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest. 2006;116(7):1802-12.
7. Maitland ML, Schilsky RL. Clinical trials in the era of personalized oncology. CA Cancer J Clin. 2011;61(6): 365-81.
8. Zineh I, Pacanowski MA. Pharmacogenomics in the assessment of therapeutic risks versus benefits: inside the United States Food and Drug Administration. Pharmacotherapy. 2011;31:729-35.
9. Snyderman R, Dinan MA. Improving health by taking it personally. JAMA. 2010;303:363.
10. Popkin BM. Global nutrition dynamics: the world is shifting rapidly toward a diet linked with noncommunicable diseases. Am J Clin Nutr. 2006;84(2):289-98.
11. Schultz LO, Bennett PH, Ravussin E, Kidd JR, Kidd KK, Esparza J, et al. Effects of traditional and Western environments on prevalence of type 2 diabetes in Pima Indians in Mexico and the U.S. Diabetes Care. 2006; 29:1866-71.
12. Esparza-Romero J, Valencia ME, Martinez ME, Ravussin E, Schultz LO, Bennett PH. Differences in insulin resistance in Mexican and U.S. Pima Indians with normal glucose tolerance. J Clin Endocrinol Metab. 2010;95(11):E358-62.
13. Williamson DF, Vinicor F, Bowman BA, Centers for Disease Control and Prevention Primary Prevention Working Group. Primary prevention of type 2 diabetes mellitus by lifestyle intervention: implications for health policy. Ann Intern Med. 2004;140(11):951-7.
14. Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: a systematic review and meta-analysis. BMJ. 2007; 334:299-308.
15. Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004; 351(26):2683-93.
16. Oostdam N, van Poppel MNM, Wouters MGAJ, van Mechelen W. Interventions for preventing gestational diabetes mellitus: a systematic review and meta-analysis. J Women's Health (Larchmt). 2011;20(10): 1551-63.
17. Pettit DJ, Lawrence JM, Beyer J, Hillier TA, Liese AD, Mayer-Davis B, et al. Association between maternal diabetes in utero and age at offsping's diagnosis of type 2 diabetes. Diabetes Care. 2008;31:2126-30.
18. Dyer JS, Rosenfeld CR. Metabolic imprinting by prenatal, perinatal, and postnatal overnutrition: a review. Semin Reprod Med. 2011; 29(3):266-76.
19. Yajnik C. Early life origins of insulin resistance and type 2 diabetes in India and other Asian countries. J Nutr. 2004;134(1):205-10.
20. Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care. 2003; 26(4):977-80.
21. Herman WH. The economics of diabetes prevention. Med Clin North Am. 2011;95(2):373-84.
22. Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X. Costeffectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care. 2010;33:1872-94.
23. Reis JP, Loria CM, Sorlie PD, Park J, Hollenbeck A, Schatzkin A. Lifestyle factors and risk for new-onset diabetes. Ann Intern Med. 2011;155: 292-9.
24. Sullivan SD, Garrison LP Jr., Rinde H, Kolberg J, Moler EJ. Costeffectiveness of risk stratification for preventing type 2 diabetes using a multi-marker diabetes risk score. J Med Econ. 2011;14(5):609-16.
25. Hardy BJ, Séguin B, Goodsaid F, Jimenez-Sanchez G, Singer PA, Daar AS. The next steps for genomic medicine: challenges and opportu-nities for the developing world. Nat Rev Genet. 2008;9(Suppl 1):S23-7.
26. Meigs JB, Shrader P, Sullivan LM, McAteer JB, Fox CS, Dupuis J, et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med. 2008;359:2208-19.
27. Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet. 2010;42(7):579-89.
28. Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med. 2008;359: 2220-32.
29. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, et al. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011;17(4):448-53.
30. Suhre K, Shin SY, Petersen AK, Mohney RP, Meredith D, Wagele B, et al. Human metabolic individuality in biomedical and pharmaceutical research. Nature. 2011;477:54-60.
31. Cirulli ET, Goldstein DB. Uncovering the roles of rare variants in common disease through wholegenome sequencing. Nat Rev Genet. 2010;11:415-25.
32. McCaffery JM, Jablonski KA, Franks PW, Dagogo-Jack S, Wing RR, Knowler WC, et al. TCF7L2 polymorphism, weight loss, and proinsulin: insulin ratio in the Diabetes Prevention Program. PLoS One. 2011;6(7):e21518.
33. Merikangas KR, Risch N. Genomic priorities and public health. Science. 2003;302:599-601.
34. Daar AS, Singer PA, Persad DL, Pramming SK, Matthews DR, Beaglehole R, et al. Grand challenges in chronic non-communicable diseases. Nature. 2007;450:494-6.
35. Ritchie LD, Sharma S, Ikeda JP, Mitchell RA, Raman A, Green BS, et al. Taking action together: a YMCA-based protocol to prevent type-2 diabetes in high-BMI innercity African American children. Trials. 2010;11:60.